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Background and Aims Research suggests that tobacco smokers may develop psychosis at an earlier 
age than non-smokers, with effects on psychotic symptoms. We aimed to test the difference in age 
of onset of psychosis between smokers and non-smokers . Design Self-report data was collected 
from smokers and non-smokers in a population of first episode psychosis patients. Setting 
Outpatient first episode psychosis programme in Santander (Cantabria), Spain. Participants Three 
hundred and ninety seven patients (226 male, 171 female) who agreed to take part between 2001 
and 2011.  Measurements Age of onset of psychosis, age of smoking initiation, demographics, family 
history of psychosis, and cannabis use were collected by self-report. Findings Kaplan-Meier analysis 
showed that smokers had a significantly lower mean age of psychosis onset (smokers=27.4 (±8.1) 
years, non-smokers=30.5 (±9.9) years) than non-smokers (χ²(1)=11.72, p=0.001). The Cox 
Proportional Hazard’s Model showed no significant difference in the age of psychosis onset between 
smokers and non-smokers adjusted for covariates (hazard ratio (HR)=1.034,95% Confidence interval 
(CI) 0.828-1.291). Age of psychosis onset was significantly predicted by cannabis use (HR=2.073, 95% 
CI 1.633-2.633) and gender (HR=1.706,95% CI 1.363-2.135). Conclusions Smokers do not appear to 
have a significantly earlier age of psychosis onset than non-smokers after taking into account 
cannabis use and gender.  
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Introduction 
Tobacco smoking has been highly recognised as being associated with psychosis, due to its high 
prevalence rate in those with severe mental illness compared to the general population (1,2). 
Increasing attention is being focused toward the suggestion that there is a relationship between 
tobacco smoking and onset of psychotic illness (3,4).  
Varied explanations have emerged as to why tobacco smoking is so prevalent in those with severe 
mental illness. Firstly, individuals may smoke to relieve the negative symptoms less affected by 
antipsychotics, an idea which has been supported by Jiang et al. (5). Secondly, to reduce medication 
side effects via the modulation of dopamine (6), and thirdly, to provide an anxiolytic effect (6). 
A recent meta-analysis of 23 studies suggested that daily tobacco smokers developed psychosis an 
average of 1.38 years earlier than non-smokers (4).The authors commented that these results bring 
the self-medication hypothesis into question (4), as patients are smoking before onset of symptoms. 
Furthermore, the association between tobacco use and age at onset of psychosis has been found to 
persist despite controlling for confounders such as sex and cannabis use (7). Conversely, some 
research has suggested that smokers had a later age of onset than non-smokers (8), however in this 
study, ‘smokers’ were classified as people who smoked ≥7 cigarettes a week in the past month, so 
this could include some sporadic smokers. In a meta-analysis of 29 studies, there was found to be no 
association between smokers and non-smokers in age at the onset of psychotic illness (9).  
Research has also suggested that smoking tobacco may help alleviate some symptoms. Jiang et al. 
(5) found a significant improvement in negative psychotic symptoms in male patients with tobacco 
use. There was no effect of tobacco use on positive symptoms. Similar results have been found by 
other studies (10). Conversely, some studies have found no effect of smoking on either positive or 
negative symptoms in people with psychosis (11). However, a large study of  patients with 
schizophrenia revealed a significantly higher Positive and Negative Syndrome Scale (PANSS) score in 
heavy smokers compared to mildly dependant smokers and non-smokers (12), as did Krishnadas et 
al. (13), who also found higher PANSS negative scores in those with mild-moderate dependence. 
Based on the findings of recent meta analyses (4,9), we hypothesised that  firstly smokers were 
more likely to have an earlier age of onset of psychosis than non-smokers. Secondly, due to the 
higher symptomatology scores seen in those with tobacco dependence in previous studies (13), it 
was hypothesised that smokers would have higher symptom scores than non-smokers at initial 
presentation. Thirdly, if tobacco use does have an impact upon psychiatric symptomatology we 
would expect a poorer treatment response in smokers, therefore it was hypothesised that smokers 
would have a poorer response to treatment than non-smokers.  
 
Methods 
Design 
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Three hundred and ninety seven patients were assessed on various measures at baseline, with some 
outcomes also measured as week six, after a period of randomised antipsychotic treatment. A 
computer generated list was drawn up by a statistician, and patients were allocated by simple 
randomisation to receive either olanzapine (5-20mg/day), risperidone (3-6mg/day, haloperidol (3-
9mg/day), quetiapine (100-600mg/day), ziprasidone (40-160mg/day) or aripiprazole (5-30mg/day). 
All information was obtained at baseline, except for psychotic symptomatology, which was also 
measured at week six. This study is part of a clinical trial in first episode psychosis (Clinical 
Programme of First Episode Psychosis; PAFIP). 
 
Measures 
Tobacco cigarette use per day and the age at which the patient initiated smoking regularly (daily) 
was obtained in person by self-report. Patients who did not smoke were classified as ‘non-smokers’, 
those who smoked <20 a day were classified as ‘smokers’, and those who smoked ≥20 a day were 
classified as ‘heavy smokers’. Non-daily tobacco (N=2) and non-daily cannabis smokers (N=16) were 
classified as users, and former smokers were classified as non-smokers. 
Duration of untreated illness (DUI) was defined as the time from the first unspecific psychosis 
symptoms (there should be no return to the previous stable level of functioning) to initiation of an 
adequate antipsychotic drug treatment. Duration of untreated psychosis (DUP) was defined as the 
time from the first continuous psychotic symptom present most of the time, to initiation of 
adequate antipsychotic treatment. Age of onset of psychosis was defined as the age at which the 
first continuous psychotic symptoms emerged.  
Psychotic positive and negative symptoms were assessed with the SAPS and Scale for the 
Assessment of Negative Symptoms (SANS,(14)) respectively. Years of exposure to tobacco prior to 
illness was calculated by subtracting the age of initiation of tobacco use from age of onset of 
psychosis. SAPS and SANS measurements were conducted at baseline and after the first six weeks of 
pharmacological treatment.  
Demographic information including sex was measured at baseline, cannabis use (yes/no), and the 
age at which this was started to be smoked regularly (daily) was also obtained in person by self-
report. Family history of psychosis was defined as having a first degree relative with a diagnosis of a 
psychotic illness (yes/no). These variables were chosen based on previous research in the area of 
tobacco use and the onset of psychosis (15,16). Diagnoses were confirmed using the Structured 
Clinical Interview for DSM-IV (SCID-I) (17) carried out by an experienced psychiatrist. Our operational 
definition for a “first episode of psychosis” included individuals with a non-affective psychosis who 
have not received previously antipsychotic treatment regardless of the duration of psychosis. 
Symptom assessment was undertaken by the same assessor. 
 
Study Setting and Financial Support  
Patients were recruited from the inpatient and outpatient units at the University Hospital Marqués 
de Valdecilla, Santander (Cantabria), Spain. The site serves an epidemiologic catchment area 
population of 555,000 people. A more detailed description of this population has been previously 
published (18). 
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Funding for the study was provided by the Mental Health Services of Cantabria. The study 
conformed to international standards for research ethics, and was approved by the local institutional 
ethics committee. 
 
Subjects 
Patients were eligible if they met the following criteria: 1) were aged 15 to 60 years, 2) were 
experiencing their first episode of psychosis, 3) were living in the catchment area, 4) met the DSM-IV 
criteria for a brief psychotic disorder, delusional disorder, schizophreniform disorder, schizophrenia, 
schizoaffective disorder or psychosis not otherwise specified, 5) had no prior treatment with 
antipsychotic medication, or if previously treated, a total lifetime of adequate antipsychotic 
treatment of less than 6 weeks, 6) were able to understand the aims of the study and signed an 
informed consent form, and 7) had current psychotic symptoms of moderate or greater severity 
assessed by one of the five items of the Scale for the Assessment of Positive Symptoms (SAPS, (19)). 
Patients were excluded for the following reasons: 1) they met DSM-IV criteria for drug dependence, 
2) mental retardation, or 3) they had a history of neurologic disease or head injury. Between 2001-
2011, 522 individuals were referred to the PAFIP first episode program. A final sample of 397 
patients was considered for the present study (see Figure 1 for participant flow-chart). 
Figure 1: Participant flow-chart. 
Statistical Methods 
Categorical variables were summarised as n (percentage), and continuous variables as means and 
standard deviations (SD), baseline sociodemographic and clinical characteristics were tested with 
one-way-ANOVAs for continuous variables, or χ2 tests for the categorical variables.  
Kaplan-Meier analysis was conducted on age of onset of psychosis, and smoking status (yes/no), and 
a second analysis on age of onset of psychosis and stratified smoking level (non-smoker, smoker and 
heavy smoker). The Cox Proportional Hazard’s model was conducted to model the separate effects 
of gender, level of tobacco use, cannabis use, and family history of psychosis (yes/no) on age of 
onset of psychosis. A further analysis was conducted to model the effects of all these variables 
combined on age of onset of psychosis, with smoking type set as the categorical predictor. Main 
confounders (sex, cannabis use (yes/no), family history of psychosis (yes/no)) were entered as 
dichotomous covariates in the model. Non-smokers were considered to be the reference category. 
One-way ANCOVAs were used to compare smokers and non-smokers in terms of SAPS/SANS score at 
initial presentation, adjusting for sex, age, DUP, cannabis use (yes/no) and family history of psychosis 
(yes/no) . Finally, one-way ANCOVAs were used to compare smokers and non-smokers in terms of 
SAPS/SANS score at six weeks. Baseline score on SAPS/SANS were used as a covariate, along with 
sex, age, DUP, cannabis use (yes/no) and family history of psychosis (yes/no). Significance level was 
set a priori at p<0.05 and all methods were 2-tailed. Data was analysed using SPSS 21 (IBM Corp., 
Armonk, NY). 
 
Results 
Clinical and demographic characteristics of the sample are shown in Table 1. The mean age of the 
whole sample was 29.8 (±9.46) years, 56.9% were male, and 44.3% were unemployed. A family 
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history of psychosis was reported in 33.4% of total patients, and the majority of patients had a 
diagnosis of schizophrenia (69%). The mean age of onset of psychosis in all patients was 28.7 (± 9.0) 
years old, and the mean age of initiation of daily smoking was 15.9 (±3.0) years. Therefore the 
patients who were smokers had been smoking for an average of 12.5 (±8.2) years before the onset 
of psychosis. All smokers initiated smoking before the onset of psychotic symptoms. Patients 
smoked an average of 19.35 (±9.2) cigarettes per day at baseline. The average DUI in all patients was 
25.3 (±40.6) months and mean DUP was 13.8 (±30.8) months. At baseline, the mean SAPS score was 
13.5 (±4.3) and mean SANS score was 7.1 (±6.3). Stratified by smoking status, patients did not differ 
in terms of total SAPS/SANS scores at baseline, DUI, age at smoking initiation or diagnosis (all p’s 
>0.05), but significantly differed in sex, age, age at onset of psychosis, employment (yes/no), 
cannabis use (yes/no), and DUP (all p’s <0.05). In the sample there were a total of 164 ‘non-
smokers’, 80 ‘smokers’ and 153 ‘heavy smokers’. 
Table 1: Clinical and demographic characteristics of patients, stratified by level of tobacco use. 
Age of Onset of Psychosis 
Kaplan-Meier analysis showed that smokers had a significantly lower mean age of psychosis onset 
(smokers=27.4 (±8.1) years and non-smokers=30.5 (±9.9) years) than non-smokers (χ²(1)=11.72, 
p=0.001, see Figure 2). When smoking status was stratified into level of smoking, there was a 
significant difference between the ages of psychosis onset in non-smokers (30.49 (±9.9) years) and 
heavy smokers (27.2 (±7.6) years) (χ²(1)=14.359, p<0.001). 
Cox Proportional Hazard was conducted to assess the effect of smoking type on time to psychosis 
onset in years, adjusting for potential confounders. Non-smokers were the reference category, and 
smoking type was set as a categorical predictor (yes/no). The hazard ratio (HR) for smokers after 
taking into account sex, cannabis and family history was 1.034 times that of a non-smoker. This was 
not significant (see Figure 3). The results showed that cannabis use and sex had significant effects on 
age of onset of psychosis (see Table 2 for adjusted and unadjusted Cox Proportional Hazard results. 
 
Figure 2: Kaplan Meier survival curve of smoking status and age at onset of psychosis.
a 
 
Figure 3: Cumulative survival curve of smoking status and age at onset of psychosis.a 
 
Table 2: Adjusted and unadjusted hazard ratios for the association between age of onset of 
psychosis and tobacco use. 
 
Psychopathology and Treatment Response  
The ANCOVA analysis for SANS scores at baseline showed no significant difference between smokers 
and non-smokers when adjusting for covariates (F(1,390)=1.226,p=0.269). The only significant 
independent predictor of SANS score at baseline was DUP (F(1,390)=5.342,p=0.021). Similarly, there 
was no significant difference between smokers and non-smokers on SAPS score at baseline 
(F(1,390)=0.142,p=0.706) when adjusting for covariates. There was however a significant 
relationship between SAPS score at baseline and cannabis use (F(1,390)=4.375,p=0.037).  
The ANCOVA analysis comparing change between SANS scores at baseline and at week-6, showed no 
significant difference between smokers and non-smokers when adjusting for covariates 
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(F(1,388)=1.112,p=0.292). Similarly, there was no significant difference between smokers and non-
smokers on SAPS score at week-6 (F(1,388)=1.363,p=0.244) when adjusting for covariates.  
 
Discussion 
Initial Kaplan-Meier analysis demonstrated that smokers had a significantly earlier age of onset of 
psychosis when compared to non-smokers. However, after controlling for cannabis use, sex and a 
family history of psychosis, all well-known factors contributing to psychosis risk (15,20), there was no 
effect of smoking status on the age of onset of psychosis. Variables that were significantly associated 
with an earlier age of onset of psychosis were sex and current use of cannabis.  
The findings contradict those of Gurillo et al. (4), as there was found to be no effect of smoking 
tobacco on the age of onset of psychosis in the present study. Therefore, the results also go against 
the idea that smoking tobacco is associated with a later age of onset of psychosis as found by Ma et 
al. (8). However, in many studies investigating the effect of tobacco use on the age of psychosis 
onset, information regarding the use of substances such as cannabis is often unavailable (8), or 
limited (4). Gurillo et al. (4) found that the age of onset in smokers is significantly earlier than in non-
smokers (24.3 years vs 25.6 years respectively). The authors noted that because onset of smoking is 
earlier than symptom onset (ages of smoking initiation and psychosis onset not available), this brings 
the self-medication hypothesis into question. In the present sample, all patients started smoking 
(15.9 (±3.0) years) before the onset of their symptoms (27.4 (±8.1) years), also bringing the self-
medication hypothesis into question. However, despite these findings, the overall risk of smokers 
versus non-smokers of developing psychosis at an earlier age was close to non-significance. This 
could explain the differing results between Gurillo et al. (4) and the present study. Furthermore 
Gurillo et al. (4) identified that the studies used in the meta-analysis comparing smokers versus non-
smokers were case-control studies, and when the analysis was restricted to only studies disclosing 
cigarette use per day the association between age of onset and tobacco use was no longer 
significant.  Our findings support those of Myles et al. (8), as there was no significant difference in 
the age of onset of psychosis between smokers and non-smokers. The authors noted that the effect 
of tobacco use on psychosis age of onset may have been confounded by concurrent cannabis use in 
some patients, and furthermore, some of the studies included in analysis were different to those use 
by Gurillo et al. (4), which may account for their differing results. 
 
Previous studies have observed less severe negative symptoms in smokers (5,10).  Jiang et al. (5) 
found that in males with acute schizophrenia, negative symptom scores were significantly lower in 
those that smoke (HR=0.080, p=0.021) compared to non-smokers. Similarly, Smith et al. (10) found 
that smoking also led to lower mean negative symptom scores as measured by the PANSS (9.4 
(±4.09) pre-test compared to 7.2 (±2.70) post-test) in inpatients diagnosed with schizophrenia or 
schizoaffective disorder. However in the present study there was no effect of smoking on either the 
positive or negative symptoms at initial presentation in patients with first episode psychosis.  
Our results contradict the finding of  Krishnadas et al. (12) and  Aguilar et al. (11).  Krishnadas et al. 
(12) interviewed 131 adults diagnosed with schizophrenia. The results showed significant differences 
between non-smokers, mildly dependent smokers and severely/highly dependent smokers in 
positive and negative symptom scores (13).  Aguilar et al. (11) found that, in a sample of 250 out-
patients diagnosed with schizophrenia, smokers had significantly higher scores on psychotic 
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symptoms as measured by the PANSS compared to non-smokers. The findings of our study support 
those of Barnes et al. (11),who observed no significant difference in the positive or negative 
symptom scores in smokers and non-smokers. This sample was comprised of 146 outpatients and 
inpatients diagnosed with chronic schizophrenia, and was verified by expired carbon-monoxide 
levels (11). 
Particular strengths of this study include the large sample size (N=397). Few studies have evaluated 
the relationship between smoking tobacco and the age of onset of psychosis, along with the effect of 
tobacco smoking on psychopathology of patients presenting with first episode psychosis. This study 
provides an accurate estimate of the effect of tobacco smoking on psychopathology and age of 
onset of psychosis, in patients presenting with their first episode, and is representative of first 
episode psychosis cases in this geographical area. 
One key limitation of this study is that tobacco cigarette use was not biochemically verified. 
However research has shown that there is close comparability between self-reported and 
biochemical measures of tobacco smoking in people with psychosis (21). Another key limitation to 
this study is the potential for recall bias in recalling the age of initiation of smoking. It is also possible 
that the characteristics of the patients in the present study are not generalisable to those not 
presenting with their first episode of psychosis.  
On the basis of these results, we can conclude that smoking tobacco has no effect on the age of 
onset of psychosis after taking into account cannabis use. Similarly, tobacco smoking also had no 
effect on psychopathology at initial presentation or treatment response at six weeks. Previous 
studies that have reported a relationship between tobacco and psychosis may be biased by cannabis 
use.  Therefore, to be able to take into account the effect of smoking on psychosis age of onset and 
psychopathology we need to consider the use of cannabis in patients presenting with first episode 
psychosis. 
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Figure 1: Participant flow-chart. 
 
 
  
  
 
This article is protected by copyright. All rights reserved. 
Figure 2: Kaplan Meier survival curve of smoking status and age at onset of psychosis.
a 
 
a
 Kaplan Meier survival curve. Proportion surviving refers to the proportion of patients not yet having a 
diagnosis of a psychotic illness. 
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Figure 3: Cumulative survival curve of smoking status and age at onset of psychosis.
a
 
 
 
 
a
 Cox Proportional Hazard model, with cannabis use (yes/no), family history of psychosis (yes/no) and sex as 
covariates. Proportion surviving refers to the proportion of patients not yet having a diagnosis of a psychotic 
illness. 
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Table 1: Clinical and demographic characteristics of patients, stratified by level of tobacco use. 
 
 
  
 All 
(N=397) 
Non-smoker 
(N=164) 
Smoker 
(N=233) 
Non-smoker vs 
Smoker  
Mean SD Mean SD Mean SD t (df=1) p 
Age, yrs 
Age at psychosis onset, yrs 
Age at smoking onset, yrsa 
DUI,months
b 
DUP,monthsc 
Total SAPS at baseline 
Total SANS at baseline 
 
29.8 
28.7 
15.9 
25.3 
13.8 
13.5 
7.1 
 
 
N 
9.5 
9.0 
3.0 
40.6 
30.8 
4.3 
6.3 
 
 
% 
32.2 
30.5 
- 
30.6 
19.2 
13.2 
6.68 
 
 
N 
10.5 
9.9 
- 
52.6 
42.2 
4.31 
6.04 
 
 
% 
28.2 
27.4 
15.9 
21.7 
10.0 
13.7 
7.3 
 
 
N 
8.3 
8.1 
3.0 
29.4
18.2 
4.36.
4 
 
 
% 
-4.002 
3.306 
- 
1.921 
2.609 
1.235 
1.04 
 
χ2 
(df=1) 
<0.001 
0.001 
- 
0.056 
0.010 
0.217 
0.299 
 
p 
Sex (Male) 
Diagnosis 
Schizophrenia 
Other primary 
psychotic disorder 
Unemployed (Yes)d 
Cannabis Use (Yes) 
226 
 
274 
123 
 
176 
171 
56.9 
 
69.0 
31.0 
 
44.3 
43.1 
75 
 
106 
58 
 
6324 
45.7 
 
64.6
35.4 
 
38.4
14.6 
151 
 
168 
65 
 
113 
147 
64.8 
 
72.1
27.9 
 
48.7
63.1 
14.283 
 
2.518 
 
 
4.122 
92.168 
<0.001 
 
0.284 
 
 
0.042 
<0.001 
a 
smoker N=123,  
b
non-smoker N=157, smoker N=230,  
c
non-smoker N=163, 
d 
smoker N=232 
 
DUI=Duration of untreated illness, DUP=Duration of untreated psychosis, SANS=Scale for the Assessment of Negative 
Symptoms, SAPS=Scale for the Assessment of Positive Symptoms 
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Table 2: Adjusted and unadjusted hazard ratios for the association between age of onset 
of psychosis and tobacco use. 
 
 Hazard Ratio 95% Confidence Interval p 
Unadjusted 
Adjusted for sex 
Adjusted for cannabis use 
Adjusted for  family history of 
psychosis 
Adjusted for all covariates 
0.703 
2.062 
2.451 
0.973 
 
1.034 
0.574-0.861 
1.669-2.548 
1.982-3.031 
0.766-1.235 
 
0.828-1.291 
0.001 
<0.001 
<0.001 
0.820 
 
0.767 
 
 
 
